In-transit melanoma: an individualized approach

Oncology (Williston Park). 2011 Dec;25(14):1340-8.

Abstract

The majority of locoregional recurrences in melanoma occur in the form of intradermal or subcutaneous local or in-transit metastasis. In-transit melanoma represents contamination of the lymphatic space that, if treated, can result in long-term cure in a subset of patients. The management of in-transit metastases is challenging, since the treatments and extent of disease vary greatly based on the number, depth, location, and distribution of lesions, and on their biological behavior. A number of different treatment options exist, but there is no level 1 evidence to guide clinical decision-making. Herein we present our institutional treatment algorithm, which allows for individualization based on the patient's presentation.

MeSH terms

  • Algorithms*
  • Antineoplastic Agents / administration & dosage*
  • Chemotherapy, Cancer, Regional Perfusion
  • Electrochemotherapy
  • Humans
  • Injections, Intralesional
  • Lasers, Dye / therapeutic use
  • Lymphatic Metastasis
  • Melanoma / secondary*
  • Melanoma / therapy*
  • Neoplasm Recurrence, Local / pathology*
  • Neoplasm Staging
  • Skin Neoplasms / pathology*
  • Skin Neoplasms / therapy*

Substances

  • Antineoplastic Agents